REMASTer: Recurrent Brain Metastases After SRS Trial
This study is for people with brain metastases (cancer that has spread to the brain) that have come back after stereotactic radiosurgery (SRS), a type of radiation therapy. It is testing different treatment approaches, including radiation therapy (either after surgery or not at all), steroid therapy, and Laser Interstitial Thermal Therapy (a minimally invasive procedure using the NeuroBlate® System to destroy tumors with heat). The study aims to see how well these treatments prevent the cancer from growing (progressive disease) and how well they help patients stop using steroids without needing more care for radiation necrosis (damage to healthy brain tissue from radiation). You may be able to join if you are 18 or older and have brain metastases from cancer outside the brain, confirmed by an MRI scan.
- Study design
- This is an interventional study that plans to enroll 261 participants. It is a randomized study, meaning participants will be assigned to different treatment groups by chance.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- For the progressive disease group, participants will be followed from the date of randomization until the cancer progresses or they pass away, for up to 24 months. For the radiation necrosis group, participants will be assessed for three months from randomization to see if they can stop steroids without needing more care.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
REMASTer: REcurrent Brain Metastases After SRS Trial
At a glance
Conditions
Where it's being run
9 sites across 7 statesStudy leadership
- Peter Fecci, MD · PRINCIPAL_INVESTIGATOR · University of Colorado, Denver
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Progressive Disease CohortFrom date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Determine the effectiveness of LITT using the NeuroBlate® System with or without repeat SRS on recurrent brain metastases, as measured by freedom from local progression.
- Radiation Necrosis CohortAssessed for a three month period from time of randomization to steroid freedom without escalation of care.
Determine the effectiveness of LITT using the NeuroBlate System versus standard medical management as measured by time to steroid independence without escalation of care, measured in days from LITT procedure, defined as freedom from steroids for a period of four weeks without escalation of care.